Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Amazon Stock Rises as Meta Expands AWS Partnership for AI Infrastructure 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
Mercedes-Benz Faces Rising Competition in China but Rejects Price War Strategy 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
European Car Sales Surge in March as EV and Hybrid Demand Accelerates 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
U.S. Raises Alarm Over Chinese AI Firms’ Alleged IP Theft Through Model Distillation 
DeepSeek Launches V4 AI Models with Enhanced Reasoning and 1M Token Context Window 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Florida Investigates OpenAI and ChatGPT Over Alleged Role in FSU Shooting 
LG Innotek Stock Hits Record High on $68M Automotive Wi-Fi 7 Deal 
SK Hynix to Invest $13 Billion in AI Chip Packaging Facility 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
AMSTERDAM, the Netherlands, March 2, 2016 -- uniQure N.V. (NASDAQ:QURE), a leader in human gene therapy, announced today that its management will present at the 36th Cowen & Company Healthcare Conference to be held on March 7 – 9, 2016 at the Boston Marriott Copley Place, Boston, Massachusetts.
Date: March 9, 2016
Time: 11:20 a.m. EST / 5:20 p.m. CET
Speaking for uniQure: Daniel Soland (Chief Executive Officer)
The live webcast, including a slide presentation, can be accessed through the following link: http://wsw.com/webcast/cowen30/qure or by accessing the link displayed in the "Events" section on the "Media" page of the uniQure website at: http://www.uniqure.com/news/calendar-of-events/. The replay of the webcast will be available after the conclusion of the live event and archived on the uniQure website for at least 30 days following the webcast.
About uniQure
uniQure is delivering on the promise of gene therapy – single treatments with potentially curative results. We are leveraging our modular and validated technology platform to rapidly advance a pipeline of proprietary and partnered gene therapies to treat patients with CNS, liver/metabolic and cardiovascular diseases. www.uniQure.com
CONTACT: uniQure:
Eva Mulder
Direct : +31 20 240 6103
Main: +31 20 240 6000
[email protected]
Media inquiries:
Gretchen Schweitzer
MacDougall Biomedical Communications
Direct: +49 172 861 8540
Main: +49 89 2424 3494 or +1 781 235 3060
[email protected]
